Prescription Drug Costs

More has changed about Medicare prescription drug coverage in the past two years than in the previous decade. A hard cap on what you can spend on drugs each year is now in effect. The federal government is negotiating prices directly with drug manufacturers for the first time in Medicare’s history. A program to cover certain weight-loss medications is moving forward. And a new initiative is bringing international drug pricing into Medicare’s framework.

These changes do not all arrive on the same schedule, and they do not all affect every Medicare enrollee equally. Some will substantially lower costs for people who take expensive specialty medications. Others are more relevant to people managing diabetes or obesity. Understanding which changes apply to your situation, and when, is the practical work this article is designed to help you do.

The $2,000 Out-of-Pocket Cap

#

Before 2025, Medicare Part D drug coverage had no ceiling on what you could spend in a year. If you took expensive medications, you could move through the deductible, then the initial coverage phase, then the coverage gap, and then into catastrophic coverage, accumulating thousands of dollars in out-of-pocket costs along the way. Some beneficiaries on high-cost cancer drugs, biologics, or specialty medications were spending $5,000, $7,000, or more per year just on their prescriptions.

That structure no longer exists. Starting in 2025, the maximum you will pay out of pocket for Part D prescription drugs in a calendar year is $2,000. This cap counts your deductible, your copayments, and your coinsurance. Once you have paid $2,000 in covered drug costs, your plan pays 100 percent for the rest of the year.

The people who benefit most are those with expensive medications: specialty drugs for autoimmune conditions, cancer treatments, HIV medications, and high-cost biologics. If you were previously spending well above $2,000 per year on your medications, this change represents a meaningful reduction in your annual drug costs.

Medicare also introduced an option called the Medicare Prescription Payment Plan, sometimes referred to as the M3P, which allows you to spread your drug costs across monthly payments rather than paying them when you fill a prescription. If you tend to reach high drug costs early in the year, this option can smooth out the cash flow burden. You would enroll through your Part D plan, and your monthly payments would be adjusted based on what you have already spent and what you are projected to spend for the rest of the year. The total you pay does not change, only the timing.

It is worth confirming that your plan is applying the cap correctly. If you believe you have been charged more than $2,000 in covered drug costs in a calendar year, contact your plan and then 1-800-MEDICARE if the issue is not resolved.

Drug Price Negotiation

#

For the first time in the program’s history, Medicare can negotiate the prices of certain drugs directly with pharmaceutical manufacturers. This authority came from the Inflation Reduction Act of 2022, and the first round of negotiated prices took effect in 2026.

The initial group of drugs subject to negotiation was selected based on their cost to Medicare and the availability of competing treatments. The specific drugs in the first negotiation cohort include medications for blood clots, diabetes, heart failure, and other conditions with large Medicare populations. If you take one of these drugs, your cost-sharing at the pharmacy may have decreased because the underlying price CMS pays has been reduced.

You will not necessarily see a line item on your receipt that says “negotiated price.” What you may notice is a lower copayment or coinsurance when you fill the prescription. If your cost has not changed and you believe your medication was among those subject to negotiation, ask your pharmacist or your plan directly.

Additional drugs will enter the negotiation process in 2027 and in subsequent years. The law requires CMS to expand the list progressively. The long-term effect of negotiation on drug costs for Medicare beneficiaries is expected to be substantial, though it will accumulate gradually rather than arriving in a single year.

GLP-1 Weight Loss Drugs

#

Medications like Ozempic, Wegovy, and Zepbound belong to a class called GLP-1 receptor agonists. They were originally developed for diabetes management, and several carry FDA approval for that use. Some formulations have since received separate FDA approval for chronic weight management. These are among the most prescribed and most expensive drugs in the United States.

Standard Medicare Part D covers GLP-1 drugs when they are prescribed for diabetes, because Part D covers FDA-approved medications for covered indications. The coverage gap has been for the weight-loss indication specifically. When a GLP-1 is prescribed for weight management rather than diabetes, standard Part D has not covered it.

A CMMI innovation model called BALANCE is testing broader GLP-1 coverage for weight management in selected markets. The program links drug coverage to participation in a structured lifestyle program, meaning you would likely need to be enrolled in a qualifying weight management program to receive the benefit. Clinical criteria for eligibility typically include a body mass index above a defined threshold, often combined with a weight-related condition like high blood pressure or pre-diabetes.

The BALANCE program is not yet available everywhere, and the coverage it offers is tied to the model’s test markets and participation requirements. If you are currently paying out of pocket for a GLP-1 for weight management, ask your doctor and your plan whether BALANCE coverage is available in your area. If it is not, it is worth asking your plan whether your specific situation might qualify for coverage through an exception or appeal process, particularly if you have a clinical condition that the medication also addresses.

Under the $2,000 annual cap, if your plan does cover a GLP-1, your total out-of-pocket drug cost for the year regardless of that drug’s price cannot exceed $2,000. That is meaningful given that GLP-1 medications can cost several hundred dollars per month at retail.

The GUARD Program

#

Alongside negotiation, CMS is implementing a program called GUARD, which is designed to benchmark certain Medicare drug prices against prices paid in other developed countries. The reasoning is straightforward: the same medications often cost substantially less in Canada, Germany, France, and other nations with government-negotiated pricing, and CMS is exploring mechanisms to bring those price differentials into the American system.

GUARD applies to a specific set of drugs and will have the most impact on medications where the international price differential is largest. For beneficiaries, the effect will appear as lower cost-sharing when you fill an affected prescription, similar to the mechanism through which negotiated prices will show up. You are unlikely to receive a direct notification that a drug you take has moved into the GUARD framework; the change will appear at the pharmacy counter.

The program is newer and less broadly implemented than the IRA negotiation process. Its scope is expected to expand over time, but in the near term it affects a more limited drug set than the negotiation program.

Finding the Lowest-Cost Part D Plan for Your Medications

#

The most practical drug coverage decision you make each year is which Part D plan to be in. This matters whether you have a standalone Part D plan alongside Original Medicare or a Medicare Advantage plan with drug coverage built in.

Plans differ in which drugs they cover and at what tier, meaning at what cost-sharing level. A drug your doctor prescribes might be a preferred generic on one plan’s formulary, meaning you pay a few dollars per fill, and a non-preferred brand on another plan’s formulary, meaning you pay a much higher share. The premium difference between two plans may be small relative to the difference in what you pay for your specific medications.

The Medicare Plan Finder at medicare.gov allows you to enter your exact medications, including dosage and frequency, and compare the estimated annual cost across every plan available in your zip code. The tool will show you a total estimated cost that includes the premium, the deductible, and your expected drug cost-sharing based on your medication list. That total is what matters, not the monthly premium in isolation.

Before open enrollment each fall, run this comparison for your current medications. If your plan changed the tier for any of your drugs, the Plan Finder will show that. If a different plan now offers substantially better coverage for the same drugs, the difference can be hundreds of dollars over the course of the year.

Your pharmacist is an underused resource for this kind of question. Pharmacists see what plans cover and at what cost, and many are willing to walk through a Plan Finder comparison with you or point you to lower-cost options including manufacturer assistance programs for people who qualify. State Health Insurance Assistance Program counselors provide the same service free of charge, with no financial interest in any plan you choose.

Related Reading

#

MCR-04_09 Part D in 2026-2027: Drug Negotiation, Formulary Disruption, and the BALANCE Bridge MCR-01_09 GLOBE and GUARD: MFN Drug Pricing Arrives in Medicare